Details of risk–benefit communication in informed consent documents for phase I/II trials

BACKGROUND: Informed consent documents for clinical studies should disclose all reasonably foreseeable risks and benefits. Little guidance exists on how to navigate the complexities of risk–benefit communication, especially in early clinical research. Practice-oriented development of such guidance s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahrass, Hannes, Bossert, Sabine, Schürmann, Christopher, Strech, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Ethics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876653/
https://www.ncbi.nlm.nih.gov/pubmed/33231107
http://dx.doi.org/10.1177/1740774520971770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876653/
https://www.ncbi.nlm.nih.gov/pubmed/33231107
http://dx.doi.org/10.1177/1740774520971770

Ejemplares similares